February 2021
Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension study

Nel A, van Niekerk N, Van Baelen B, Malherbe M, Mans W, Carter A, Steytler J, van der Ryst E, Craig C, Louw C, Gwetu T, Mabude Z, Kotze P, Moraba R, Tempelman H, Gill K, Kusemererwa S, Bekker L-G,... More »
February 2021
Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study

Baeten JM, Palanee-Phillips T, Mgodi NM, Mayo AJ, Szydlo DW, Ramjee G, Mirembe BG, Mhlanga F, Hunidzarira P, Mansoor LE, Siva S, Govender V, Makanani B, Naidoo L, Singh N, Nair G, Chinula L, Parikh... More »
February 1 2021
Dapivirine ring OLE study results featured in The Lancet HIV

Primary results from two open-label extension studies (OLEs) of IPM’s dapivirine vaginal ring, DREAM and HOPE, are featured in The Lancet HIV’s February 2021 issue. The publications mark an important... More »
January 28 2021
New Report Finds that R&D Partnerships Have Produced Dozens of Lifesaving Health Innovations Since 2010

Novel product development model that offers cost-effective way to target infectious and neglected diseases has 375 innovations under development SILVER SPRING, Md. (January 28, 2021)—The public-... More »
January 27 2021
IPM Welcomes WHO’s Recommendation for Dapivirine Vaginal Ring as New Women’s HIV Prevention Option

WHO recommends the monthly ring be offered as part of a combination prevention approach for women at substantial HIV riskSILVER SPRING, Md. (January 27, 2021)—The nonprofit International Partnership... More »